Markers and their ratio to determine the risk for early-onset preeclampsia
OwnerJoost Henric Nicolaas SCHUITEMAKERinventor
Life of this patent
Estimating the term…
Abstract
The application discloses new biomarkers for early-onset preeclampsia based on the finding that the ratio between GBP-1 and ESM-1 in plasma samples was significantly increased in women that develop severe early-onset pre-eclampsia compared to healthy control pregnancies: the ratio between GBP-1 and ESM-1 is a prognostic parameter to identify the women at risk for severe early-onset pre-eclampsia as early as 12±2 weeks of gestation and can serve both as an important rule-in and rule-out parameter.
Claims24
An in vitro method for identifying from a biological fluid sample from a pregnant subject a pregnancy related syndrome selected from the group consisting of Preeclampsia, Eclampsia, Hemolysis Elevated Liver enzymes and Low Platelets (HELLP), and IUGR, the method including
- (i) determining a first parameter that scales with the concentration of GBP-1 in said biological fluid sample and a second parameter that scales with the concentration of ESM-1 in said biological fluid sample, and defining a ratio of the first parameter and the second parameter;
- (ii) comparing this ratio of the first and the second parameter with a reference value, wherein the reference value is a reference ratio of GBP-1 and ESM-1 of a subject having a healthy pregnancy;
- and
- (iii) identifying the subject as being likely to have or develop a healthy pregnancy based on the comparison of the ratio of the first parameter and the second parameter and the reference ratio.
(canceled)
(canceled)
A device for identifying from a biological fluid sample from a pregnant subject a pregnancy related syndrome selected from the group consisting of Preeclampsia, Eclampsia, Hemolysis Elevated Liver enzymes and Low Platelets (HELLP), and IUGR, said device comprising (a) an analyzing unit configured to determine a first parameter that scales with the concentration of GBP-1 in said biological fluid sample and a second parameter that scales with the concentration of ESM-1 in said biological fluid sample;
- (b) an evaluation unit comprising a data processor having implemented necessary algorithms for determining a ratio between the first parameter and the second parameter and comparing the ratio to a reference value stored in a database in order to determine whether a pregnant subject is likely to have or develop preeclampsia, eclampsia, HELLP, and/or IUGR, wherein the reference value is a reference ratio of GBP-1 and ESM-1 of a subject having a healthy pregnancy.
(canceled)
A kit for identifying whether a pregnant subject being in any one of week 10-36 gestation is likely to have or develop a pregnancy related syndrome selected from the group consisting of Preeclampsia, Eclampsia, HELLP, and IUGR, said kit comprising:
- (a) an analyzing unit comprising a detection agent for ESM-1 and an analyzing unit comprising a detection agent for GBP-1;
- (b) an evaluation unit for determining whether a pregnant subject is likely to have or develop the pregnancy related syndrome, based on a result provided by the analyzing unit, comprising an evaluation unit comprising a data processor having implemented necessary algorithms for comparing the concentrations of GBP-1 and ESM-1, or their ratio, to one or more of sFlt1, VEGF, P1GF, HGF, sEndoglin, pp-13, PAPP-A, GDF-15, pikachurin and hemopexin determined with reference values stored in a database and calculate the ratio between the measured markers in order to determine whether a pregnant subject is likely to have or develop the pregnancy related syndrome.
(canceled)
Dependencies are inferred from the claim text.